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Abstract: In patients with idiopathic pulmonary arterial hypertension (iPAH), iron deﬁciency is common and has been associated with
reduced exercise capacity and worse survival. Previous studies have shown beneﬁcial effects of intravenous iron administration. In this
study, we investigated the use of intravenous iron therapy in iron-deﬁcient iPAH patients in terms of safety and effects on exercise
capacity, and we studied whether altered exercise capacity resulted from changes in right ventricular (RV) function and skeletal muscle
oxygen handling. Fifteen patients with iPAH and iron deﬁciency were included. Patients underwent a 6-minute walk test, cardiopulmo-
nary exercise tests, cardiac magnetic resonance imaging, and a quadriceps muscle biopsy and completed a quality-of-life questionnaire
before and 12 weeks after receiving a high dose of intravenous iron. The primary end point, 6-minute walk distance, was not signiﬁcantly
changed after 12 weeks (409 ± 110 m before vs. 428 ± 94 m after; P = 0.07). Secondary end points showed that intravenous iron
administration was well tolerated and increased body iron stores in all patients. In addition, exercise endurance time (P < 0.001) and
aerobic capacity (P < 0.001) increased signiﬁcantly after iron therapy. This coincided with improved oxygen handling in quadriceps
muscle cells, although cardiac function at rest and maximal V
:
O2 were unchanged. Furthermore, iron treatment was associated with
improved quality of life (P < 0.05). In conclusion, intravenous iron therapy in iron-deﬁcient iPAH patients improves exercise endurance
capacity. This could not be explained by improved RV function; however, increased quadriceps muscle oxygen handling may play a role.
(Trial registration: ClinicalTrials.gov identiﬁer NCT01288651)
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Iron deﬁciency is common in patients with idiopathic pulmonary
arterial hypertension (iPAH) and is closely associated with poor sur-
vival and low exercise capacity.1-3 Compromised oxygen handling—
that is, oxygen transport and consumption at a skeletal muscle level—
has been suggested to cause the decreased exercise capacity in
iron-deﬁcient (ID) iPAH patients.2,4 Furthermore, iron deﬁciency
might lead to deterioration of right ventricular (RV) function.5 We
have shown that oral iron supplements are ineffective in restoring
body iron stores in iPAH.1,2 Recently, it was demonstrated that in-
travenous iron treatment in ID iPAH patients was associated with
higher serum iron levels, improved 6-minute walk distance (6MWD),
and quality of life.6,7However, the exactmechanisms bywhich iron im-
proves clinical performance in iPAH patients remain to be elucidated.
Therefore, the aim of the present study was twofold: (1) to in-
vestigate whether intravenous iron therapy in ID iPAH was safe
and could indeed restore iron levels and improve exercise capacity
in another iPAH cohort and (2) to explore whether altered exercise
capacity can be explained in part by improved RV function and im-
proved skeletal muscle oxygen handling.
METHODS
Patient inclusion
Patients who visited the Pulmonology Department of the Vrije Uni-
versiteit University Medical Center between January 2011 and Jan-
uary 2013 were approached to participate. Inclusion criteria were
iPAH as deﬁned by the European guidelines,8 receipt of optimal
PAH-speciﬁc treatment, being clinically stable for at least 3 months,
and presence of iron deﬁciency (serum iron level of <10 μmol/L,
transferrin saturation of <15% [women] or <20% [men], and serum
ferritin level of <100 μg/L). Patients were excluded if they received
iron therapy at admission, participated in another pulmonary hyper-
tension study medication trial, or had a history of anemia, liver func-
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tion impairment, or any other acute or chronic condition other than
iPAH. The study was registered at ClinicalTrials.gov (NCT01288651)
and was approved by the Institutional Review Board on Research
Involving Human Subjects (Amsterdam, Netherlands). All patients
provided written informed consent before inclusion.
Clinical study design
All end points were measured before (baseline) and 12 weeks af-
ter intravenous iron therapy. The primary end point was change
in 6MWD after iron therapy. Secondary end points were change in
blood iron parameters, change in maximal exercise parameters and
endurance capacity determined by maximal and submaximal cardio-
pulmonary exercise tests (CPETs), RV function determined by car-
diac magnetic resonance imaging (MRI), pulmonary function deter-
mined by means of spirometry and diffusion capacity measurements,
quality of life determined by the SF-36 questionnaire, and skeletal
muscle oxygen handling at the cellular level determined by quad-
riceps muscle biopsy. A detailed description of all tests and methods
is provided in the appendix (available online). After baseline mea-
surements, an intravenous infusion of ferric carboxymaltose (Ferinject;
Vifor Pharma, Glattbrugg, Switzerland) at 1,000 mg was given, in
20 mL of NaCl 0.9% over 2 hours. The study was not placebo con-
trolled, since no permission for a placebo group was given by the
medical ethics committee. At the end point of the study, 12 weeks
after ﬁrst admission, all measurements were repeated in the same
order.
Statistical analysis
All data from patients before and after iron administration were
analyzed using the paired Student t test or repeated-measures analy-
sis of variance with Bonferroni post hoc tests to correct for mul-
tiple measurements. All analyses were performed with GraphPad
Prism (ver. 5.00; GraphPad Software, San Diego, CA) and SPSS
(ver. 20.0; SPSS, Chicago, IL). Log transformation was performed
to obtain a normal distribution of the data when necessary. Data
are presented as mean ± standard deviation, unless stated other-
wise. Differences with a P value of <0.05 were considered statisti-
cally signiﬁcant.
RESULTS
Tolerability and effects on blood iron levels
Eighteen iPAH patients were included in this study, of whom three
did not ﬁnish the protocol. One patient presented with atrial ﬂutter
during second admission, 1 patient withdrew from the study before
ﬁnishing the protocol, and 1 patient was excluded because erythro-
poietin was administered to that patient in another hospital during
the follow-up period. Baseline characteristics of the 15 patients who
were analyzed are shown in Table 1. All patients received the total
amount (1,000 mg) of intravenous iron after the baseline measure-
ments were obtained. Two patients had minor complaints of frontal
headache during the infusion, which resolved shortly thereafter. No
other adverse events were noted. Serum iron parameters were sig-
nificantly increased 12 weeks after iron administration, without a
change in N-terminal prohormone of brain natriuretic peptide levels.
Serum hepcidin values were low at baseline and remained low until
the end of the study (Table 2).
Iron improved submaximal exercise capacity
Intravenous iron therapy did not signiﬁcantly change 6MWD after
12 weeks (409 ± 110 m before vs. 428 ± 94 m after; P = 0.07; Fig. 1A).
Maximal workload (55 ± 23 W before vs. 59 ± 27 W after; not
signiﬁcant [NS]) and peak oxygen uptake (0.97 ± 0.22 L/min before
vs. 0.97 ± 0.26 L/min after; NS), determined by maximal CPET, were
also unchanged by iron therapy (Table S1; Tables S1–S4 are avail-
able online). However, the time to reach anaerobic threshold was
signiﬁcantly increased after iron therapy (175 ± 33 seconds before vs.
238 ± 43 seconds after; P < 0.001; Fig. 1B; Table S1). Exercise endur-
ance capacity was markedly improved, as iPAH patients were able
to exercise 51% longer after iron therapy compared with baseline
Table 1. Baseline patient characteristics
Value
General characteristics
Sex, no.
Male 1
Female 14
Age, years 57 ± 13
NYHA functional class, no.
II 9
III 6
Body mass index 30.1 ± 5.7
Pulmonary hypertension treatment
Single ERA, no. 4
Single prostanoids, no. 4
Combination ERA/PDE5 inhibitor, no. 2
Combination ERA/prostanoid, no. 1
Triple therapy ERA/PDE5/prostanoid, no. 4
Treatment duration, months 70 ± 42
Hemodynamic parameters at diagnosis
Mean pulmonary arterial pressure, mmHg 46 ± 15
Mean right atrial pressure, mmHg 7 ± 4
Pulmonary vascular resistance, dyn-s/cm5 672 ± 394
Cardiac output, L/min 5.7 ± 2.7
Cardiac index, L/min/m2 2.9 ± 1.3
Arterial saturation, % 94 ± 4
Mixed venous saturation, % 69 ± 10
Note: Except where otherwise noted, data are mean ± standard
deviation. Hemodynamic parameters were obtained from right heart
catheterization performed during the pulmonary hypertension diag-
nosis period. NYHA: New York Heart Association; ERA: endothelin
receptor antagonist; PDE5: phosphodiesterase 5.
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(269 ± 89 seconds before vs. 405 ± 210 seconds after; P < 0.001; Fig. 1C ;
Table S2). Spirometry parameters were unchanged after iron therapy
(Table S3).
Iron administration improved quality of life
Quality of life was improved after iron treatment, as indicated by
a higher total score in the SF-36 questionnaire (47% ± 19% before
vs. 56% ± 19% after; P < 0.05). Subdivision of the different com-
ponents of the questionnaire showed that mental health was sig-
niﬁcantly better after iron treatment (49% ± 10% before vs. 60% ±
17% after; P < 0.01), whereas physical health was unaltered (39% ±
20% before vs. 46% ± 20% after; P = 0.09).
Improved exercise capacity could not be explained
by improved RV function
Three patients could not undergo cardiac MRI because of obesity
or claustrophobia; therefore, cardiac MRI was performed in a sub-
set of 12 patients. Cardiac function at rest, represented by cardiac
index (2.8 ± 0.9 L/min/m2 before vs. 2.5 ± 0.8 L/min/m2 after; NS)
and ventricular ejection fraction (left ventricle [LV]: 62% ± 12%
Table 2. Laboratory parameters in idiopathic pulmonary arterial hypertension
patients at baseline and end point
Before iron After iron P
C-reactive protein, mg/L 7 ± 8 5 ± 4 NS
Hemoglobin, g/dL 13.4 ± 1.7 15.1 ± 1.5 NS
Hematocrit, L/L 0.40 ± 0.05 0.45 ± 0.06 NS
Erythrocytes, ×1012/L 4.8 ± 0.6 5.2 ± 0.7 NS
Mean corpuscular volume, fL 82 ± 4 88 ± 3 NS
Creatinine, μmol/L 74.3 ± 15.7 71.7 ± 15.3 NS
NT-proBNP,a ng/L 1,339 ± 2,545 1,753 ± 4,559 NS
Serum iron, μmol/L 9.6 ± 4.8 16.1 ± 6.1 <0.05
Total iron binding capacity, μmol/L 73 ± 10 61 ± 9 <0.001
Transferrin saturation, % 13.6 ± 6.7 27.3 ± 13.4 <0.001
Serum ferritin,a μg/L 44 ± 79 199 ± 225 <0.05
Soluble transferrin receptor,a nmol/L 36 ± 15 25 ± 7 NS
Interleukin 6, pg/mL 3.2 ± 0.5 3.2 ± 0.3 NS
Hepcidin,a ng/mL 4.5 ± 4.5 6.6 ± 4.4 NS
Note: Data are mean ± standard deviation and were analyzed using repeated-
measures analysis of variance with Bonferroni post hoc tests to correct for multiple
measurements. NS: not signiﬁcant; NT-proBNP: N-terminal prohormone of brain
natriuretic peptide.
a Data were log transformed to obtain a normal distribution.
Figure 1. Exercise capacity in iron-deﬁcient idiopathic pulmonary arterial hypertension patients before and after iron administration. Six-
minute walk distance (6MWD) was unchanged after iron therapy (A). Time to anaerobic threshold (AT) during maximal cardiopulmonary
exercise testing (CPET) was signiﬁcantly postponed after iron therapy (B). At a submaximal level (75% of maximum achieved workload
during CPET), patients were able to bike 51% longer after iron therapy (C ).
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before vs. 59% ± 14% after; RV: 40% ± 21% before vs. 39% ± 21%
after; both NS), was unchanged by iron therapy. In addition, LV
and RV free wall mass index remained stable (LV: 59 ± 15 g/m2 before
vs. 62 ± 17 g/m2 after; RV: 51 ± 29 g/m2 before vs. 56 ± 31 g/m2 after;
bothNS; Table S4).
Skeletal muscle oxygen transport was enhanced after
intravenous iron therapy
Twelve patients consented to a quadriceps muscle biopsy. In
2 patients, the biopsy procedure did not result in sufﬁciently high-
quality material. Biopsy analysis was therefore performed in a subset
of 10 patients. Myoglobin concentration (0.34 ± 0.17 mM before vs.
0.44 ± 0.11 mM after; P < 0.05) and mitochondrial oxidative capacity
(0.06 ± 0.01 nmol/mm3/s before vs. 0.09 ± 0.02 nmol/mm3/s after;
P < 0.05) were both signiﬁcantly increased in low oxidative cells
after iron therapy, as was total myoglobin protein content (0.5 ±
0.4 AU before vs. 1.1 ± 0.6 AU after; P < 0.05; Figs. 2, 3). Further-
more, the number of capillaries per myocyte in the quadriceps mus-
cle (1.0 ± 0.4 cap/myocyte before vs. 1.2 ± 0.2 cap/myocyte after;
P = 0.37) was similar after iron therapy (Figs. 2, 3).
DISCUSSION
In the present study, we investigated the effects of iron therapy in
ID iPAH patients. We showed that intravenous iron therapy in
ID iPAH patients increased exercise endurance capacity. This could
not be explained by better RV function; however, skeletal muscle bi-
opsies of these patients revealed improvements in oxygen handling
capacity after iron treatment.
Intravenous iron safely increased body iron stores
and quality of life
Patients received a single ﬁxed high dose of intravenous iron. An
alternative approach would have been to supply multiple smaller
doses using the Ganzoni formula to calculate the total amount
of iron needed to restore body iron.5,9-11 One reason for using the
present approach was that ferric carboxymaltose (Ferinject) is safe to
administer in high iron dosages (up to 1,000 mg at one time) and
allowed a single visit for every patient.12 Second, use of the Ganzoni
formula may not be reliable in iPAH patients with hypoxemia-driven
erythropoiesis and consequent hemoglobin (Hb) levels within the
normal range despite iron deﬁciency.11,13 Third, previous studies
with iron therapy showed that the mean dose of iron needed was
around 1,000 mg or even higher.10 One of the concerns was that pa-
tients might increase their Hb levels above reference values, which
could be detrimental since this increases blood viscosity. However,
although we observed a slight increase in Hb after iron treatment,
it was not above the upper limit of normal. In addition, in contrast
to oral iron treatment, which does not produce a response in 44%
of ID iPAH patients, ferric carboxymaltose led to higher iron stores
in all patients, as represented by increased ferritin levels.2
Figure 2. Oxygen handling in quadriceps muscle ﬁbers after iron therapy in iron-deﬁcient idiopathic pulmonary arterial hypertension
patients. Myoglobin concentration was unaltered in high oxidative cells after iron therapy (A); however, a signiﬁcant increase was ob-
served in low oxidative cells (B) and total myoglobin protein content (C). Mitochondrial oxidative capacity, expressed as maximal oxygen
consumption (V
:
O2max) in high oxidative cells, was unchanged by iron therapy (D). In low oxidative cells, V
:
O2max was higher after iron
therapy (E).
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Furthermore, intravenous iron therapy was accompanied by
improved quality of life, as shown by a mean increase of 9 points
on a 100-point scale. Better quality of life after iron therapy has
been previously described in ID patients with left heart failure
as well as those with pulmonary hypertension.5,6 Whether the ob-
served improvement is a result of better exercise capacity or an inde-
pendent result of iron therapy, however, is difﬁcult to determine.
Iron and exercise capacity
The achieved distance in the 6-minute walk test (6MWT) was
unchanged by iron therapy. In addition, maximal CPET results
were also unaltered. However, in the submaximal CPET, a signiﬁ-
cant improvement in exercise endurance time and improved aero-
bic capacity was demonstrated. It seems contradictory that the
6MWT, which is mostly regarded to be a submaximal exercise test,
was unchanged by iron therapy. This might be explained in part
by the very different type of exercise (i.e., biking vs. walking). In ad-
dition, the 6MWT has been associated with higher aerobic capacity
and less metabolic stress than the CPET, which might indicate a
different effect of iron therapy in both exercise tests.14 Also, any
potential beneﬁcial effect on the 6MWT is difﬁcult to extrapolate
to resting pulmonary hemodynamics.15 To observe changes in he-
modynamics after iron therapy in future studies, right heart cathe-
terization should be performed.
Iron deﬁciency by itself (without pulmonary hypertension) has
been associated with diminished exercise capacity and fatigue in
Figure 3. Quadriceps biopsy samples from idiopathic pulmonary arterial hypertension (iPAH) patients. Shown are typical examples of
quadriceps biopsy samples from iPAH patients before (A, C, E) and after (B, D, F) intravenous iron therapy. A, B, Myoglobin staining. C, D,
Succinate dehydrogenase activity staining. Type I and II cells are distinguished by color, as type I cells have more myoglobin and succinate
dehydrogenase activity (darker cells) than type II cells. E, F, CD31 staining. Every yellow dot represents a capillary.
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otherwise healthy subjects,16-18 although improvements in exercise
capacity were observed only when anemia was also present.4,18-21 In
the present study, increased Hb or higher maximal V
:
O2 did not ex-
plain the improved exercise endurance. Although Hb levels were
slightly higher after iron therapy (nonsigniﬁcant), there was no
signiﬁcant correlation with exercise endurance time (data not shown),
which corresponds with previous ﬁndings in iPAH patients where
the absence or presence of anemia did not inﬂuence 6MWD.2,5 In
addition, maximal V
:
O2 was unaltered after iron therapy and could
thus not explain the better exercise endurance. Other mechanisms
that may play a role in better exercise endurance are improved car-
diac function, increased skeletal muscle oxygenation, and reduced
pulmonary vascular resistance.14
Intravenous iron did not alter cardiac function but
enhanced skeletal muscle oxygen handling
Iron therapy did not improve RV function in iPAH patients. However,
it is difﬁcult to relate cardiac function at rest with exercise parameters.
In addition, restoring iron levels at the cellular level might have
beneﬁcial effects in the long term by improving cellular oxygen han-
dling in the RV, similar to the alterations in skeletal muscles after
intravenous iron treatment.
Alterations in skeletal muscle oxygen handling may have been
responsible for the improved exercise endurance capacity with iron
treatment. A relationship between skeletal muscle ID and reduced
exercise capacity has been suggested previously in ID rats and hu-
mans (without PH).17,19,22,23 We showed an increase in myoglobin
and mitochondrial oxidative capacity in low oxidative cells after iron
therapy, suggesting a higher capacity for intracellular oxygen trans-
port.
Iron and the lungs
Besides negatively inﬂuencing oxygen transport, it has been sug-
gested that ID also has direct effects on the lungs. Under hypoxic
conditions and at high altitude, ID resulted in an increase in pul-
monary arterial pressure in otherwise healthy subjects.24,25 This
has been mainly attributed to stabilization and transcription of
hypoxia-inducible factors linked to contraction, proliferation, and
migration of pulmonary artery smooth muscle cells.25-27 Another
proposed concept is that (ID-induced) anemia may limit the con-
version of nitrite to nitric oxide, thereby inhibiting the antiprolifer-
ative and vasodilatation effects of nitric oxide on the pulmonary vas-
culature.28-30 Because the present study did not include right heart
catheterization, we can only hypothesize about the alterations in
the pulmonary circulation in ID iPAH patients. However, Howard
et al.31 are currently performing a similar clinical study in the United
Kingdom in which right heart catheterization is performed, and this
study may provide more mechanistic insights into pulmonary vas-
cular changes.
Limitations
The two main limitations of the present study were that we did
not include a placebo group and right heart catheterization was not
performed. However, a larger placebo-controlled trial that includes
this measurement is currently pending in the United Kingdom.31
Conclusions
Intravenous iron therapy in ID iPAH patients increased iron stores
and was well tolerated without signiﬁcant adverse events. 6MWD
was unaltered by iron therapy, but endurance capacity improved sig-
niﬁcantly after iron therapy. This could not be explained by altered
RV function at rest; however, increased skeletal muscle oxygen han-
dling at the cellular level might be a cause.
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